Assessment of Platelet Function in Acute Ischemic Stroke Patients Previously Treated with Aspirin

Autores de IIS La Fe

• Aida Lago Martín

  Autor

• Vera Parkhutik Matveeva

  Autor

• José Ignacio Tembl Ferrairo

  Autor

• Juana Valles Giner

  Autor

• Maria Teresa Santos Diaz

  Autor

• Antonio Moscardó Martínez

  Autor

Grupos

• Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

Abstract

Background: Platelet inhibition measured by platelet function tests could be critical to understand the reasons for early recurrence and to guide therapeutic recommendations. We assess the platelet function during the acute phase of ischemic stroke in patients pretreated with aspirin who continue their treatment with aspirin only, are started on clopidogrel only, or add clopidogrel to aspirin. Methods: Sixty-four patients were taking aspirin before the stroke. Depending on the administered antiplatelet, 3 groups were defined: ASA: patients who continued on aspirin orally or intravenous acetylsalicylate of lysine, n = 30; CLO: patients who discontinued aspirin and were started on clopidogrel, n = 16; and ASA + CLO: patients who were prescribed both aspirin and clopidogrel, n = 10. Collagen-induced thromboxane A(2) (TXA(2)) synthesis, ADP (adenosine diphosphate)-induced aggregation, and occlusion time (PF-100) were measured. Results: CLO group only had a marked elevation of TXA(2) (17.44 +/- 15.62 ng/mL, P = .000) and a shortening of the platelet function analyzer (PFA)-100 closure time (157.13 +/- 88 seconds, P = .047) compared with the other 2 groups (ASA: TXA(2), .62 +/- 1.59 ng/mL; ASA + CLO: TXA(2) 1.79 +/- 4.59 ng/mL). They achieved a small (13%) but significant reduction of ADP-induced aggregation (87.00 +/- 23.06 mm, P = .008) compared with the ASA group (102.82 +/- 22.38 seconds). Conclusions: Stopping aspirin intake within the first 72 hours of the acute stroke drastically increases TXA(2) synthesis. During the same time window, the freshly prescribed clopidogrel manages to reduce the ADP-induced aggregation only slightly (13%). This study offers analytic proof that the common practice of replacing aspirin with clopidogrel does not leave stroke patients fully protected during the first days after an ischemic stroke. Possible solutions could be to preserve aspirin during a few days or to use loading doses of clopidogrel at hospital admission.

Keywords

• Antiplatelet; ischemic stroke; aspirin; clopidogrel